This was in notable contrast to control TCRs targeting tumour-associated antigens (e.g., gp100, Trp2, Tyrp1), which typically elicited activity with exposure to unmodified B16F10 cells in vitro (Fig. 3a, Supplementary Fig. 5). The gene discussed is PMEL; the disease is neoplasm.